METAP2, methionyl aminopeptidase 2, 10988

N. diseases: 78; N. variants: 12
Disease: Obesity ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028754
Disease: Obesity
Obesity 		0.040 Biomarker disease BEFREE The biomarkers described here can aid decision-making in early clinical trials of MetAP2 inhibitors for the treatment of obesity. 31537613 2019
CUI: C0028754
Disease: Obesity
Obesity 		0.040 GeneticVariation disease BEFREE This multicentre randomised double-blind placebo-controlled clinical trial assessed the efficacy and safety of a methionine aminopeptidase 2 (MetAP2) inhibitor, beloranib, in individuals with obesity (BMI ≥30 kg/m<sup>2</sup>) and type 2 diabetes (HbA<sub>1c</sub> 53-97 mmol/mol [7-11%] and fasting glucose <15.6 mmol/l). 29992370 2018
CUI: C0028754
Disease: Obesity
Obesity 		0.040 Biomarker disease BEFREE Although investigation of beloranib has ceased, inhibition of MetAP2 is a novel mechanism for treating hyperphagia and obesity. 28556449 2017
CUI: C0028754
Disease: Obesity
Obesity 		0.040 Biomarker disease BEFREE We tested the methionine aminopeptidase 2-inhibitor beloranib (ZGN-440) in 2 male rat models of obesity, one modeling hypothalamic obesity with a combined medial hypothalamic lesion (CMHL) and the other modeling a monogenic form of obesity with MC4r mutations (MC4r knockout [MC4rKO]). 27849360 2017